Selene Therapeutics
Ness Ziona · Founded 2020
About Selene Therapeutics
Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by the regulation of the neuronal activity set point by a reduction of the neuronal mean firing rate (MFR). Selene aims to develop small molecule inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrial membrane and participating in several key cellular homeostatic processes.
Company Facts
- Founded: 2020
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Oct 2020)
- Website: selenetx.com
- Phone: +972523872598
Social Profiles
Canonical: https://fsome.com/organization/selene-therapeutics-8417095 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.